1	Identifying functional genes and pathways towards a unifying model for atrial fibrillation
2	Sojin Youn Wass, MD, ¹ * Erik J. Offerman, MD, ⁶ * Han Sun, MS, ³ Jeffrey Hsu, PhD, ¹ Julie H. Rennison,
3	PhD, ¹ Catherine C. Cantlay BS ¹ , Meghan L. McHale, BA, ¹ A. Marc Gillinov, MD, ^{2,4} Christine Moravec,
4	PhD, ^{1,2} Jonathan D. Smith, PhD, ^{1,2,5} * David R. Van Wagoner, PhD, ^{1,2} * John Barnard, PhD, ³ * Mina K.
5	Chung, MD ^{1,2,5} *
6	From: The Departments of ¹ Cardiovascular and Metabolic Sciences and ³ Quantitative Health Sciences,
7	Lerner Research Institute, and the Departments of ⁴ Cardiothoracic Surgery and ⁵ Cardiovascular Medicine,
8	Heart & Vascular Institute, ² Cleveland Clinic Lerner College of Medicine of Case Western Reserve
9	University, Cleveland Clinic, Cleveland, OH, 6 Department of Internal Medicine, New York University
10	School of Medicine, New York, NY. *Equal contributions
11	
12	Short title: AF gene coexpression and pathway analyses
13	Subject codes: Atrial fibrillation, Mechanisms, Translational Studies
14	Word count: 7625
15	
16	Send correspondence to:
17	Mina K. Chung, MD
18	Department of Cardiovascular Medicine
19	Cleveland Clinic
20	9500 Euclid Ave., J2-2
21	Cleveland, OH 44195
22	chungm@ccf.org
23	Phone: 216-444-2290
24	

- 1 ABSTRACT
- 2

Rationale: Genome wide association studies (GWAS) have associated >100 genetic loci with 3 atrial fibrillation (AF), yet the biological pathways of AF remain elusive. 4 5 **Objective:** To determine candidate causal genes associated with AF risk loci and their 6 coexpression partners, modules, biologic and mechanistic pathways. Methods and Results: Cis-expression quantitative trait loci (eQTLs) were identified for 7 8 candidate genes near AF risk single nucleotide polymorphisms (SNPs) in human left atrial 9 tissues. Genes were categorized into 3 sets according to likelihood of being a causative AF gene: 1) All Candidate Genes (with significant eQTLs or previously prioritized); 2) Any eQTL Genes 10 (with ≥ 1 significant eQTL); and 3) Top GWAS SNP eQTL Genes (top SNP within the top 10 eQTL) 11 12 SNPs). Coexpression partners were identified for each candidate gene. Weighted gene coexpression network analysis (WGCNA) identified modules and modules with overrepresentation of candidate AF 13 14 genes. Ingenuity Pathway Analysis (IPA) was applied to the coexpression partners of each 15 candidate gene, and IPA and gene set enrichment analysis (GSEA) to each WGCNA module. 16 166 AF-risk SNPs were located in 135 distinct loci. The All Candidate Genes group contained 17 233, the Any eQTL Genes group 131 (83 novel), and the Top GWAS SNP eQTL Genes group 18 37 genes. IPA identified mitochondrial dysfunction, oxidative stress, epithelial adherens junction 19 signaling, and sirtuin signaling as the most frequent pathways. WGCNA characterized 64 20 modules; candidate AF genes were overrepresented in 8. Modules were represented by cell 21 injury, death, stress, developmental, metabolic/mitochondrial, transcription/translation, and immune activation/inflammation regulatory pathways. 22 23 Conclusions: AF candidate gene coexpression analyses suggest significant roles for cellular

24 stress and remodeling in AF. We propose a dual risk model for AF: Genetic susceptibility to AF

- 1 may not manifest until later in life, when cellular stressors overwhelm adaptive responses. These
- 2 analyses provide a resource for further functional studies on potential causal AF genes.

4 Keywords: atrial fibrillation, cellular stress, remodeling

1 INTRODUCTION

2

Atrial fibrillation (AF) affects over 33.5 million worldwide, is strongly associated with aging and 3 obesity, and is projected to increase further with the aging population and increasing prevalence 4 of obesity¹. AF is often initiated by triggers from the pulmonary vein ostia, which are targets for 5 6 AF ablation, and maintained by vulnerable atrial substrates that promote AF propagation and persistence². Atrial substrates become vulnerable from structural, electrical, and autonomic 7 remodeling promoted by conditions that can cause stretch, inflammation, oxidative stress, or 8 calcium overload². 9 10 Genome-wide association studies (GWAS) have identified multiple loci associated with AF risk; 11 the top locus is on chromosome 4q25 near PITX2, which has been implicated in pulmonary vein 12 formation³⁻⁶. Using a collection of human left atrial appendage (LAA) tissue samples, we 13 performed RNA sequencing (RNASeq) to identify cis-expression quantitative trait loci (cis-14 eQTLs), where AF GWAS SNP genotypes correlated with the expression of nearby genes; we 15 identified candidate genes and top eQTL SNPs for 12 of 23 AF GWAS loci known at that 16 time³. Since then, larger GWAS meta-analyses have identified over 100 AF risk loci, most of 17 which have not yet undergone functional analyses 5,6 . 18 19

Although some of the identified candidate genes have transcriptional products with known
function, the biological function of many remain poorly understood in the heart. Whole-genome
coexpression and pathway analysis of the candidate gene(s) associated with a target locus can
provide insights into their mechanisms and regulation that can guide further functional studies⁷.

To this end, we aimed to: 1) determine candidate causal genes associated with the expanded list
of AF risk loci by identification of cis-eQTLs in human LAA tissues; 2) identify coexpression
partners of AF candidate genes; and 3) identify biological pathways by which these genes might
function, focusing on candidate genes whose functional connections to AF are poorly
understood.

8

9 Left atrial tissue collection and processing.

Human LAA tissues were obtained from 265 patients, including 251 who underwent elective 10 cardiac surgery and 14 from non-failing unused transplant donors. Prior to 2008 verbal consent 11 was obtained and documented in a process approved by the Cleveland Clinic Institutional 12 Review Board. After this time written informed consent was obtained. Consent to use donor 13 hearts was obtained from the family. The patient population, tissue processing, genomic DNA 14 isolation, single nucleotide polymorphism (SNP) genotyping, RNA isolation and sequencing 15 have been previously reported³. Briefly, DNA was genotyped using Illumina Hap550v3 and 16 Hap610-quad SNP beadchips and SNP data imputed to the 1000 Genomes Project phase 2³. 17 RNA unstranded 100-bp paired-end sequencing was performed on the Illumina HiSeq 2000 18 platform. Gene read counts are available in the Gene Expression Omnibus database (GSE69890). 19 20

21 *Cis*-eQTL analyses

RNASeq and eQTL statistical analyses were previously described, with cis-eQTLs defined as
 being ±250 kb from the SNP³. Expression values were obtained from aligned files using HTseq⁸.

Reads were quantile normalized, and gene counts for eQTL analysis were variance-stabilized
 transformed using the R package Deseq2. Samples were analyzed in R (version 3.4.4) using the
 surrogate variable analysis (SVA) and Limma R packages. eQTL analyses were performed for
 235 samples of European descent and can be found at http://afeqtls.lerner.ccf.org3.

5

6 Determination of candidate AF risk genes

Using our mRNA-Seq eQTL database, we determined candidate genes near the top SNPs at each 7 locus published from two recent GWAS meta-analyses^{5,6}. Genes were categorized into 3 sets 8 according to likelihood of being a causative AF gene, from weakest to strongest: 1) All potential 9 candidate AF genes (All Candidate Genes), consisting of genes with significant cis-eQTLs (q 10 value <0.05) from the two GWAS meta-analyses, or if no significant eQTL was identified, then 11 the prioritized genes by Nielsen, et al^6 ; 2) Genes with at least one AF SNP associated with its 12 gene expression with q value <0.05 from our eQTL study (Any eQTL Genes); and 3) eQTL 13 genes with the top GWAS SNP within the top 10 eQTL SNPs (Top GWAS SNP eQTL Genes). 14 15 All Candidate Genes group is the most liberal and comprehensive list, including all cis-eQTL 16 genes and non-cis-eQTL genes prioritized by Nielsen et al. (including prioritized genes that were 17

18 not expressed in our LA mRNA-Seq database). This list allows for inspection of potential AF

19 genes, such as *PITX2* or other developmentally active genes that are no longer highly expressed

20 in adult left atrial appendage tissue, but which are still likely to play a significant role in AF

- 21 development. Any eQTL Genes group includes those showing evidence of a gene expression
- 22 relationship with an AF risk SNP. Top AF GWAS SNP eQTL Genes group is the most stringent

list in level of specificity, but is also the lowest in sensitivity, including genes with the highest
 level of evidence for future functional studies.

3

4 Gene coexpression analyses

Coexpression analysis was performed for all genes in the All Candidate Genes group across the 5 6 Ensembl genome database version 71. Each gene was included in individual linear models as a predictor with all other Ensembl genes as outcome, additionally controlling for AF rhythm, sex, 7 age, and surrogate variables. The number of surrogate variables was determined using the R 8 9 surrogate variable analysis (SVA) package; surrogate variables were recalculated for each of the genes. The SVA used unsupervised models to correct for the heterogeneity in gene expressions, 10 such as batch effects, unknown factors, library depth, or comorbidities like AF status, history of 11 structural heart disease, etc. We controlled the false discovery rate (FDR) of the multiple testing 12 with the R q value package. Genes were considered significantly coexpressed if q value was 13 <0.05 (Supplemental Excel 1). 14

15

Expression correlations were also performed, limiting analyses to the genes within each gene group, i.e. the correlation of each candidate AF risk gene with all other AF candidate genes was calculated. Genes with a q value <0.05 were considered significantly coexpressed. For each gene group, agglomerative hierarchical clustering with the compete linkage method was used, where genes start as singletons and are successively joined to form one cluster that contains all the genes.

22

23 Weighted Gene Coexpression Network Analysis (WGCNA)

1 WGCNA is a method to cluster genes into distinct modules by degree of connectivity determined by commonly coexpressed (as measured by correlation) genes. To construct the required 2 correlation matrix for WGCNA, first the conditional mean (log₂ scale) of LAA gene expression 3 was modeled using the limma-voom⁹ approach with an extensive set of known AF risk factors 4 and other covariates. Residuals were calculated from this model to remove mean effects and used 5 as inputs to the RSVP¹⁰ approach for estimating correlation matrices in the presence of latent 6 factors. The RSVP adjusted correlation matrix was then normalized using the spgn approach¹¹ to 7 remove the mean-variance bias common in RNA-seq data due to differential measurement error. 8 9 A weighted gene correlation network was built using the RSVP-spqn adjusted and normalized correlation matrix using the CEMiTool R package¹². Hub genes were defined as genes in the top 10 1% for intra-module connectivity (Supplemental Excel 2). 11

12

13 Candidate pathway identification

Canonical pathways, upstream regulators, and toxicity lists were identified using the Ingenuity 14 Pathway Analysis (IPA) software package (QIAGEN, Inc.). IPA uses gene expression data to 15 predict biological pathways that are activated by comparing known genes within a set of 16 pathways to expression patterns in the imported dataset. Ensemble ID number, q-value, and log 17 fold change values for coexpressed genes were imported into IPA. Coexpressed genes with q 18 values <0.05 were used for analysis. Significance of association between the data and canonical 19 20 pathways was determined by the ratio of the number of overlapping genes from our dataset to the total number of IPA dataset genes in a particular pathway, to determine the most significantly 21 affected pathways. Fisher's exact test was used to determine the p-value of association between 22 23 genes and the canonical pathway, where p < 0.05 was considered significant. Toxicity lists are

1	generated based on sets of molecules that are known to be involved in a particular type of
2	toxicity. IPA analyses were performed for the coexpression partners of each gene in the All
3	Candidate Genes group (Supplemental Excel 3-5), and for each module from the WGCNA
4	(Supplemental Excel 6). Over representation analysis (ORA) was performed on each WGCNA
5	module using the CEMiTool package ¹² and the Molecular Signatures Database ¹³ v7.1
6	(Supplemental Excel 7).
7	
8	RESULTS
9	
10	Patient characteristics of the 235 subjects have been previously described ³ .
11	
12	AF GWAS Loci SNPs. AF GWAS risk SNPs from two recently published meta-analyses were
13	aggregated to create a comprehensive list of 166 SNPs: 142 risk variants were identified by
14	Nielsen, et al ⁶ , with an additional 24 independent risk variants identified by Roselli, et al ⁵ . The
15	166 SNPs were located in 135 distinct loci (Supplemental Excel 8). The locus with the most
16	independent risk SNPs ⁶ was at 4q25, near PITX2, which had 10; loci labelled SCN10A, SCN5A,
17	KCNN3, NEURL1, RPL3L, and LINC01142 each had 3; loci LRRC10, NKX2-5, ZFHX3,
18	LINC00477, HSF2, NACA, AKAP6, RP11_380D231 (AC098798.1), FBXO32, MEX3C had 2.
19	All remaining loci were associated with 1 risk SNP.
20	
21	AF Candidate Gene Lists (Table 1). Of the 166 risk variant SNPs from the published meta-
22	analyses, 80 SNPs had significant cis-eQTL association (q<0.05) with 131 genes from our LAA
23	mRNA-Seq eQTL European- ancestry database comprising the Any eQTL Genes group. Of the

1	131 genes in this group, 83 genes had not been previously annotated by Nielsen, et al ⁶ , as
2	potential AF genes (Table 2). The functions of many of these genes are not yet known.
3	
4	The All Candidate Genes group comprised the 131 genes from the Any eQTL Genes group and
5	102 genes prioritized by Nielsen, et al ⁶ (Table 1). Of the 233 genes, 111 are known protein-
6	coding genes (Supplemental Figure 1), encoding mostly enzymes and transcription factors with
7	predominant localization in the cytoplasm (32%) or nucleus (22%) and the remaining in the
8	plasma membrane (17%), extracellular space (7%) or other (22%). By function (Supplemental
9	Figure 1), 12% encode transcription regulators, 12% enzymes, 5% transporters, 4% ion channels,
10	4% kinases, 3% peptidases, and 2% transmembrane receptors.
11	
12	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate
12 13	<i>Genes Coexpressed with Each Candidate Gene</i> . Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA
12 13 14	<i>Genes Coexpressed with Each Candidate Gene</i> . Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3
12 13 14 15	<i>Genes Coexpressed with Each Candidate Gene</i> . Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl.
12 13 14 15 16	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl. Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes.
12 13 14 15 16 17	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All CandidateGenes group, 5 AF candidate genes were not significantly expressed in our human adult LAAtissues (MIR6500, PANDAR, MIR54810, MIR548AZ, LOC101926943) and 3(ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl.Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes.C4orf32 had the highest number of coexpressed genes (1928 genes), followed by FXR2, which
12 13 14 15 16 17 18	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl. Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes. C4orf32 had the highest number of coexpressed genes (1928 genes), followed by <i>FXR2</i> , which was significantly coexpressed with 1889 genes.
12 13 14 15 16 17 18 19	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl. Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes. C4orf32 had the highest number of coexpressed genes (1928 genes), followed by <i>FXR2</i> , which was significantly coexpressed with 1889 genes.
12 13 14 15 16 17 18 19 20	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl. Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes. C4orf32 had the highest number of coexpressed genes (1928 genes), followed by <i>FXR2</i> , which was significantly coexpressed with 1889 genes.
12 13 14 15 16 17 18 19 20 21	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl. Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes. C4orf32 had the highest number of coexpressed genes (1928 genes), followed by <i>FXR2</i> , which was significantly coexpressed with 1889 genes. <i>Novel candidate genes identified by coexpression analyses</i> . Adenosine monophosphate (AMP) activated protein kinase (AMPK) alpha 2 catalytic subunit (<i>PRKAA2</i>) and calcium/calmodulin-
12 13 14 15 16 17 18 19 20 21 22	Genes Coexpressed with Each Candidate Gene. Of 233 candidate genes in the All Candidate Genes group, 5 AF candidate genes were not significantly expressed in our human adult LAA tissues (MIR6500, <i>PANDAR</i> , MIR54810, MIR548AZ, LOC101926943) and 3 (ENSG00000269728, ENSG00000255864, ENSG00000270028) were retired by Ensembl. Coexpression partners of the remaining 228 AF candidate genes ranged from 0 to 1928 genes. C4orf32 had the highest number of coexpressed genes (1928 genes), followed by <i>FXR2</i> , which was significantly coexpressed with 1889 genes. <i>Novel candidate genes identified by coexpression analyses</i> . Adenosine monophosphate (AMP) activated protein kinase (AMPK) alpha 2 catalytic subunit (<i>PRKAA2</i>) and calcium/calmodulin- dependent protein kinase II beta (<i>CAMK2B</i>) were the most common genes co-expressed with the

23 AF candidate genes that are not themselves GWAS-identified. Other commonly coexpressed

genes included prostaglandin F2 receptor inhibitor (*PTGFRN*), talin 1 (*TLN1*), sarcolemma
 associated protein (*SLMAP*), PDZ and LIM domain 5 (*PDLIM5*), and methionine sulfoxide
 reductase B3 (*MSRB3*) (Supplemental Figure 2).

4

5 Top Canonical Pathways of Coexpressed Genes. IPA was used to identify top candidate pathways of each group of genome-wide coexpressed partners for each gene in the All Candidate 6 Genes group (Supplemental Excel Folder10). After ranking IPA canonical pathways for each 7 candidate gene by p-value, the top 5 significant canonical pathways were listed for each gene 8 9 (Supplemental Excel 9). Mitochondrial dysfunction, oxidative phosphorylation, epithelial adherens junction signaling, sirtuin signaling pathway and actin cytoskeleton pathway were the 10 most frequent pathways listed among the top 5 canonical pathways (Supplemental Excel 3). For 11 the Any eQTL Genes group (Supplemental Excel 4), epithelial adherens junction signaling, 12 mitochondrial dysfunction and oxidative phosphorylation, germ cell-Sertoli cell junction 13 signaling and axonal guidance signaling were the most frequent pathways listed. For the Top 14 GWAS SNP eQTL Genes group (Supplemental Excel 5), EIF2 signaling, axonal guidance 15 signaling, sertoli cell-sertoli cell junction signaling, regulation of eIF4 and p70S6K signaling, 16 17 oxidative phosphorylation, and mitochondrial dysfunction were the most frequent pathways listed among the top 5 canonical pathways. Overall, the most frequent pathways were those 18 involved in energy and metabolism signaling, including mitochondrial dysfunction, oxidative 19 20 phosphorylation, and sirtuin signaling. Stress and injury signaling pathways were also represented and included EIF2 signaling pathways, regulation of eIF4 and p7086K signaling, 21 22 protein ubiquitination and cardiac hypertrophy signaling.

23

1	Top canonical pathways, top upstream regulators and top networks from pathway analyses
2	within each of the gene groups are shown in Supplemental Table 1.
3	
4	WGCNA Modules. WGCNA characterized 64 distinct modules from 17,357 genes expressed in
5	the LAA (Supplemental Excel 2). 48 of these modules, including a module containing
6	uncorrelated genes ('not_correlated'), contained at least one AF candidate gene. Candidate AF
7	genes were overrepresented in 8 modules (p<0.05; modules 21, 2, not correlated, 25, 11, 42, 39,
8	24). Hierarchical clustering (Figure 1) of the modules' top eigengene produced 15 clusters. A list
9	of genes for each module, alongside with hub genes that were determined by module
10	connectivity for each module are available in Supplemental Excel file 2.
11	
12	Concordant with IPA analyses, the modules with AF risk gene overrepresentation suggest that
13	AF genes are over represented in modules related to intracellular ion homeostasis,
14	metabolic/energy utilization, gene expression regulation, and signaling pathways of stress and
15	unfolded protein responses.
16	
17	The clustering of modules 25, 39, and 42 (Figure 1), suggests that genes in these three modules
18	are closely related. Gene set enrichment analyses of these 3 modules (Supplemental Excels 6 &
19	7) suggest that genes in these modules are involved in remodeling of the heart through a
20	combination of myogenesis and the unfolded protein response.
21	
22	Biological pathways of top AF candidate genes. Coexpression analyses can provide insight into
23	biological function of top AF candidate genes. These include transcription factors such as PITX2,

ZFHX3, top implicated genes by AF GWAS for which function remains elusive, as well as
 candidate causal genes in the Top GWAS SNP eQTL Genes group. IPA pathways for *PITX2* (Figure 2) and *ZFHX3* (Figure 3) are shown.

4

5 DISCUSSION

Despite having identified over 135 genetic loci associated with AF from prior meta-analyses, 6 establishing functional connections and causal genes contributing to AF pathophysiology 7 remains challenging. Here we utilized human atrial eQTL analyses to identify top candidate 8 9 causal AF genes. To advance our understanding of the biological mechanisms of these candidate genes, we identified gene coexpression partners for each candidate gene and WGCNA modules 10 that inform functional characterization using pathway and gene set analyses. This application 11 provides insight into the function of genes nearest the top AF GWAS loci, for example PITX2 12 and ZFHX3, for which connections to AF mechanisms remain challenging. 13

14

15 <u>*PITX2*</u>

The top locus implicated by AF risk GWAS is on chromosome 4q25. The nearest gene is 16 *PITX2*^{5,6}, which encodes a transcription factor that regulates left-right asymmetry during organ 17 morphogenesis, suppresses a sinus node program in the LA, and is critical to formation of the 18 pulmonary veins¹⁴, making it an attractive candidate causal gene. *PITX2* is active during cardiac 19 20 development and decreases with maturation, likely contributing to our failure to identify significant eQTLs in our adult LAA tissues. Nevertheless, PITX2 remains expressed in our adult 21 LA tissues, though in lower levels in patients with AF,³ suggesting an additional function(s) in 22 the adult LA. Top canonical pathways of genes coexpressed with PITX2 (Figure 2) include 23

1	amino acid metabolism (e.g. alanine degradation, valine, 4-aminobutyrate and glutamine
2	degradation, driven by ABAT and ALDH6A1), and major signaling pathways, such as PI3K/AKT,
3	G protein coupled receptor signaling, IGF-1, PDGF signaling, renin-angiotensin and AMPK
4	signaling pathways, all commonly mediated by the phosphoinositide-3-kinase regulatory subunit
5	1 (<i>PIK3R1</i>), and also AMPK non-catalytic subunit γ 2 (<i>PRKAG2</i>). <i>PIK3R1</i> encodes for a subunit
6	of PIK3, which is critical in insulin resistance ¹⁵ , and in the regulation of myogenic
7	differentiation, myoblast proliferation, and myotube hypertrophy ^{16,17} . The PI3K-Akt signaling
8	pathway is activated by insulin like growth factor-1 (IGF-1) ¹⁷ which is critical in regulation of
9	energy metabolism in cardiomyocytes ¹⁸ , and decreases autophagy and apoptosis ¹⁹⁻²² . Inhibition
10	of the PI3K-Akt signaling in the heart is thought to contribute to AF in patients on ibrutinib ²³ , an
11	immunotherapeutic agent that acts as a Bruton's tyrosine kinase inhibitor ²⁴ . PRKAG2 is one of
12	three AMPK regulatory subunits, and is abundant in the heart ²⁵ . PRKAG2 gain of function
13	mutations increase AMPK activity and promote accumulation of glycogen in cardiac tissues via
14	transcriptional changes in glucose handling regulators ²⁶ . PRKAG2 mutations are considered a
15	metabolic storage disease and not a disease of the sarcomeres - this is further evidenced by the
16	absence of fibrosis or myocyte disarray in patients with a mutation presenting with either
17	hypertrophic cardiomyopathy and/or conduction abnormalities ²⁷ . Increased AMPK activity and
18	the resultant glycogen accumulation are also correlated with changes in metabolic pathways and
19	AKT phosphorylation ²⁶ . The AKT signaling pathway also regulates myocyte hypertrophy ²⁸ .
20	These findings suggest that PITX2 may play a role in metabolic energy utilization and/or
21	regulation in the heart, and dysregulation may cause metabolic dysregulation and imbalance in
22	autophagy, with subsequent disease.

1 IPA analysis also highlighted fibrotic signaling pathways, driven by transmembrane protein 67 (TMEM67), cannabinoid receptor 1 (CNR1), collagen type IV a2 chain (COL4A2), insulin like 2 growth factor binding protein 5 (*IGFBP5*), adrenergic receptor β2 (*ADRB2*), plasminogen 3 activator, urokinase (PLAU), angiotensin I converting enzyme (ACE), neurofibromin 1(NF), and 4 5 Xin actin binding repeat containing 1 (XIRP1). AMPK activation inhibits Transforming Growth Factor (TGF) beta signaling and target transcripts of pathways associated with cardiac fibrosis²⁶. 6 Although *PITX2* had no prior known role in fibrosis signaling, this network pattern suggests that 7 8 *PITX2* may suppress general fibrosis and tissue remodeling pathways, perhaps by the AMPK pathway; *PITX2* loss of function may promote activation of fibrosis pathways, which may 9 10 predispose to AF.

11

PITX2 is most strongly coexpressed with *PITX2* adjacent non-coding RNA (*PANCR*), which we
reported is an upstream regulator of *PITX2²⁹*. Both are located in module 58, which contains
genes encoding ion channels (*SCN4B, ANO1, KCNJ8, CACNA1H, P2RX3, KCNT1, SCN3A*),
cytoskeletal proteins (*MYH9, ADCY3, MYO1B, MYO6*), and G protein coupled receptors. These
associations suggest further functional impact of *PITX2* on these pathways in adult atria.

18 <u>ZFHX3</u>

19 *ZFHX3* is associated with the regulation of numerous pathways, including growth and

20 differentiation of neuronal tissue³⁰, regulation of inflammation³¹, and tumor suppression through

regulation of *MYC* transcription³². *ZFHX3* has been implicated in calcium homeostasis, and

22 knock down of ZFHX3 promotes arrhythmogenesis in atrial myocytes,³³ mediated by increased

23 expression of sarcoplasmic/endoplasmic reticulum Ca2+ATPase 2a (SERCA2a), ryanodine

receptors, ultra-rapid delayed rectifier potassium currents, transient outward currents and
 acetylcholine-sensitive potassium currents.

3

4 WGCNA analysis associates ZFHX3 with module 2, which was overrepresented by AF risk genes. Hub genes of module 2 include rho guanine nucleotide exchange factor 12 (ARHGEF12), 5 6 phosphoinositide kinase, FYVE-type zinc finger containing (PIKFYVE), and kinesin family 7 member 1B (KIF1B). Gene enrichment analyses suggest module 2 likely contains genes critical 8 in mitochondrial function modulation and apoptosis. 9 10 The top canonical pathways of ZFHX3 and coexpressed genes include cell proliferation 11 pathways such as acute myeloid leukemia, and prostate cancer signaling pathways, driven by 12 KRAS, mitogen-activated protein kinase kinase 6 (MAP2K6), phosphatidylinositol-4,5bisphosphate 3-kinase catalytic subunit α (*PIK3CA*), cAMP responsive element binding protein 13 1 (CREB1), and phosphatase and tensin homolog (PTEN). RAS, PI3K and CREB gene expression 14 15 is positively associated with ZFHX3 (Figure 3). As these genes have been linked to modulation of cardiomyocyte apoptosis,^{19,22,34} ZFHX3 may also regulate apoptosis and hypertrophy of 16 cardiomyocytes. This is consistent with the top toxicity lists suggested by IPA which include 17 cardiac necrosis/cell death, cardiac fibrosis and hypertrophy, and followed by RAR activation, 18 and NRF2-mediated oxidative stress. 19 20

21

22 Identification of Novel AF Candidate Genes by Coexpression Analyses

1 Identification of genes coexpressed with GWAS-identified AF risk genes provides novel insights into AF. While not identified by GWAS as AF risk genes, these genes may also play significant 2 roles in AF pathogenesis or yield additional targets for functional studies. Based on frequency of 3 being coexpressed with the putative AF genes, we identified two genes of potential interest in AF 4 pathophysiology: *PRKAA2*, the $\alpha 2$ catalytic subunit of AMPK, and *CAMK2B*, a subunit of 5 calcium/calmodulin-dependent protein kinase II (CAMKII). 6 7 *PRKAA2* is a catalytic subunit of AMPK in the heart³⁵. AMPK plays an important role in 8 9 cellular energy and metabolism sensing and regulation. Activation of AMPK induces mitochondrial biogenesis, as well as increases insulin sensitivity and fatty acid oxidation³⁶. 10 11 AMPK activity is induced by drugs, such as metformin and thiazolidinediones³⁷. Metformin affects phosphorylation of PRKAA2³⁷. Activity of PRKAA2 increases with muscle contraction 12 and exercise³⁵. *PRKAA2* deletion causes defects in autophagy, mitochondrial fission and 13

fragmentation, and insulin resistance³⁸ in mice. In the heart, PRKAA2 deletion increases release
 of atrial natriuretic peptide, myocardial fibrosis and hypertrophy, with subsequent decrease in

ejection fraction³⁹ and arrhythmogenesis⁴⁰. In a study of 645,710 diabetics, metformin was

associated with 20% less AF⁴¹. *PRKAA2* is located in module 1. GSEA and IPA analyses suggest
genes in module 1 may be involved in cell death signaling.

19

<u>CAMK2B</u> is a subunit of calcium/calmodulin-dependent protein kinase II (*CAMKII*) that is
 expressed primarily in the brain, followed by the heart. In the heart *CAMKII* is activated by β adrenergic signaling, Gq coupled receptor signaling, presence of reactive oxygen species,
 hyperglycemia, ischemic injury, and other stimuli that cause increased intracellular calcium⁴².

1 Persistent activation of CAMKII promotes arrhythmogenesis, myocardial apoptosis and

2 necroptosis⁴³. In contrast to apoptosis that requires ATP derived from mitochondria, necroptosis

3 is mediated by opening of the mitochondrial permeability transition pore (mPTP), resulting in

4 dissipation of mitochondrial membrane potential and subsequent shutdown of the

5 mitochondria⁴². Necroptosis triggers an inflammatory response that results in tissue injury and

6 likely contributes to many cardiovascular disease processes ⁴². CAMK2B is located in module

7 22 which is associated with genes involved in myogenesis and development.

8

9 WGCNA modules with overrepresentation of AF risk genes

10 AF genes are over represented in modules related to intracellular ion homeostasis,

metabolic/energy utilization, gene expression regulation, and signaling pathways of stress and
unfolded protein response (Table 3).

13

One of the most statistically significant modules with AF over representation is module 2. Heme 14 metabolism is the hallmark pathway from GSEA for module 2. Iron deficiency is seen in patients 15 with heart failure, and portends higher mortality⁴⁴. In contrast, iron overload can result in AF⁴⁵. 16 Iron homeostasis affects mitochondrial function and ATP- linked respiration by modulating 17 activity of electron train complexes I, II and III⁴⁶. Respirometry studies from human LAA tissues 18 of patients with AF and diabetes undergoing coronary artery bypass graft surgery also implicate 19 impairment of Complexes I and II⁴⁷. In rapidly paced cardiomyocytes, mitochondrial dysfunction 20 has been linked to AF progression, mediated by activation of autophagy and endoplasmic 21 reticulum stress induction⁴⁸. One of the top canonical pathways from IPA analysis of module 1 22 23 includes Protein Kinase A (PKA) signaling. Oxidative stress activates PKA signaling in cardiac

myocytes which triggers apoptosis and reduced mitochondrial respiration⁴⁹. PKA activation
indirectly inhibits mitochondrial fission and increases mitochondrial fusion, with resultant
superoxide production and altered mitochondrial potential with increase in mitochondrial pore
permeability⁵⁰. Analysis results of module 2 from both IPA and GSEA suggest a potential
significant role of the mitochondria in AF.

6

These examples demonstrate how WGCNA modules and pathway analyses of coexpressed genes 7 can help elucidate potential function of AF risk genes, including those for which mechanistic 8 9 connections to the disease have remained poorly defined. Our overall findings are consistent with the two meta-analyses reported by Roselli et al⁵, and Nielsen et al.,⁶ but are also distinct 10 from previous findings. Roselli et al⁵ noted themes of cardiac development, electrophysiological, 11 and cardiomyocyte contractile or structural functional groups. Nielsen et al.⁶ noted cardiac 12 structural remodeling as a recurrent theme and postulated that genes active during fetal heart 13 development are reactivated in response to stress in the adult heart. We also see themes related to 14 cardiac structural change, but also discovered involvement of unfolded protein response, 15 mitochondrial and metabolic pathways, especially those of AMPK. 16

17

18 Dual Risk Model for Development of AF

Differences between the All Candidate Genes group and the Any eQTL Genes group highlight the differing expression patterns that may be present in cardiac development compared to later in life, when AF typically presents. The All Candidate Genes group contains GWAS implicated genes active in development. The Any eQTL Genes group indicate genes that are active in adult LAA, whose expression may serve as a barometer of function in the adult atria. These findings

support our proposed dual risk model for development of AF (Figure 4)⁵¹. In this model, genes 1 active during cardiac structural development contribute to genetic susceptibility to AF, for 2 example potentially by alterations in pulmonary vein development (e.g. PITX2) that may 3 contribute to pulmonary vein triggers. However, with exposure to stresses later in life, 4 transcriptional responses to cellular stress, such as metabolic stress, mitochondrial dysfunction, 5 6 oxidative stress, sirtuin signaling and abnormal proteostasis may lead to altered, overwhelmed or reduced transcriptional responses, as suggested by our prior study of differential gene expression 7 in AF⁵² and the current analyses. Indeed, AF is associated with heterogeneous cardiovascular 8 9 stressors, including aging, obesity, hypertension, coronary or valvular disease, heart failure, metabolic syndrome, sleep apnea, excessive alcohol, and extreme exertion. Thus, in genetically 10 susceptible individuals, the imbalance in transcriptional responses to stress may predispose to AF 11 occurring later in life. In addition, the imbalance or overcompensation during response to injury, 12 initially adaptive, may eventually lead to fibrosis and adverse remodeling, with eventual 13 presentation of the disease. This concept may explain why AF tends to occur later in life as 14 evidenced by the top canonical pathways in this study, including pathways involved in 15 mitochondrial dysfunction, oxidative phosphorylation and sirtuin signaling. Metabolic stressors 16 and pathways likely play a strong role in AF and suggest that AF occurrence may reflect crossing 17 the threshold of cellular resilience and adaptation. 18

19

20 Limitations and Future Studies

IPA was initially designed for use in cancer data sets and relies upon curated pathways, thus our
results may be skewed by the composition of the pathways. Some of these pathways may not
accurately reflect the pathology of cardiovascular diseases. Nevertheless, many of the top

1 canonical pathways seem relevant to AF. Pathway analyses may oversimplify mechanisms. Functional studies, including overexpression and knockdown models, are required to establish 2 causation. However, these analyses are intended to help guide such studies toward relevant 3 candidate genes and pathways. Future studies are planned or underway for several of the targets 4 identified. Our samples were from the LAA, rather than the PVs. However, PV tissue is difficult 5 6 to obtain, and the LAA is directly adjacent to the left PVs and reflects atrial function in the human adult. The left atria obtained for this study were from patients that required open heart 7 surgery, which suggests significant disease comorbidity. Here, we attempted to adjust for 8 9 heterogeneity of comorbidities with use of surrogate variable adjustments.

10

11 Conclusions

In conjunction with recent GWAS meta-analyses demonstrating 135 loci associated with risk for 12 AF, our genetic-genomic analyses in human adult LA tissue have identified 233 candidate genes, 13 of which 131 had significant eQTLs. Coexpression analyses of these gene sets identified stress 14 pathways that are implicated in AF risk. These include mitochondrial dysfunction, oxidative 15 stress, sirtuin signaling, EIF2 signaling, and protein ubiquitination pathways. WGCNA modules, 16 17 and specifically those with AF candidate genes over representation, suggest remodeling in response to injury may be occurring through changes in metabolomics, myogenesis and 18 apoptosis. We propose a dual risk model for AF, where genes active during cardiac development 19 20 contribute to genetic susceptibility to AF, for example by alterations in PV development that leads to PV triggers. In genetically susceptible individuals, development of stresses later in life, 21 22 such as those associated with aging or obesity, may lead to inadequate or overwhelmed 23 transcriptional responses to stress that can predispose to AF. Here we also identify multiple

1	genes not previously linked to AF. We have created a resource to help scientists elucidate	
2	possible functions of genes through identification of coexpressed genes with each candidate AF	
3	gene, and associated modules in the LAA via WGCNA. The components allow for better	
4	elucidation of likely AF mechanisms and potential targets for upstream therapies.	
5		
6	Sources of Funding: National Institutes of Health grants R01 HL 090620 and R01 HL 111314;	
7	American Heart Association Atrial Fibrillation Strategically Focused Research Network grant	
8	18SFRN34110067, 18SFRN34170013, 18SFRN34140065, 18SFRN34170442; the NIH National	
9	Center for Research Resources for Case Western Reserve University and Cleveland Clinic	
10	Clinical and Translational Science Award UL1-RR024989, the Cleveland Clinic Department of	
11	Cardiovascular Medicine philanthropy research funds, and the Tomsich Atrial Fibrillation	
12	Research Fund. JH was supported by the National Institutes of Health training grant T32 GM	
13	088088. JDS was supported by the Geoffrey Gund Endowed Chair for Cardiovascular Research.	
14	Disclosures: None.	
15		
16		
17	References	
18		
19	1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial	
20	fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129(8):837-47. (In	
21	eng). DOI: 10.1161/CIRCULATIONAHA.113.005119	
22	CIRCULATIONAHA.113.005119 [pii].	

1	2.	Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications
2		for management. Circulation 2011;124(20):2264-74. (In eng). DOI:
3		10.1161/CIRCULATIONAHA.111.019893.
4	3.	Hsu J, Gore-Panter S, Tchou G, et al. Genetic Control of Left Atrial Gene Expression
5		Yields Insights into the Genetic Susceptibility for Atrial Fibrillation. Circ Genom Precis
6		Med 2018;11(3):e002107. (In eng). DOI: 10.1161/CIRCGEN.118.002107.
7	4.	Liu X, Wang F, Knight AC, Zhao J, Xiao J. Common variants for atrial fibrillation: results
8		from genome-wide association studies. Hum Genet 2012;131(1):33-9. (In eng). DOI:
9		10.1007/s00439-011-1052-3.
10	5.	Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide association study for
11		atrial fibrillation. Nat Genet 2018;50(9):1225-1233. (In eng). DOI: 10.1038/s41588-018-
12		0133-9.
13	6.	Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields
14		new insight into atrial fibrillation biology. Nat Genet 2018;50(9):1234-1239. (In eng).
15		DOI: 10.1038/s41588-018-0171-3.
16	7.	Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of
17		conserved genetic modules. Science 2003;302(5643):249-55. (In eng). DOI:
18		10.1126/science.1087447.
19	8.	Anders S, Pyl PT, Huber W. HTSeqa Python framework to work with high-throughput
20		sequencing data. Bioinformatics 2015;31(2):166-9. (In eng). DOI:
21		10.1093/bioinformatics/btu638.

1	9.	Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis
2		tools for RNA-seq read counts. Genome Biol 2014;15(2):R29. (In eng). DOI: 10.1186/gb-
3		2014-15-2-r29.
4	10.	Shah RD, Frot B, Thanei G-A, Meinshausen N. Right singular vector projection graphs:
5		fast high dimensional covariance matrix estimation under latent confounding. Journal of
6		the Royal Statistical Society: Series B (Statistical Methodology) 2020;82(2):361-389. DOI:
7		10.1111/rssb.12359.
8	11.	Wang Y, Hicks SC, Hansen KD. Co-expression analysis is biased by a mean-correlation
9		relationship. bioRxiv 2020:2020.02.13.944777. DOI: 10.1101/2020.02.13.944777.
10	12.	Russo PST, Ferreira GR, Cardozo LE, et al. CEMiTool: a Bioconductor package for
11		performing comprehensive modular co-expression analyses. BMC Bioinformatics
12		2018;19(1):56. (In eng). DOI: 10.1186/s12859-018-2053-1.
13	13.	Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP.
14		Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27(12):1739-40. (In
15		eng). DOI: 10.1093/bioinformatics/btr260.
16	14.	Logan M, Pagán-Westphal SM, Smith DM, Paganessi L, Tabin CJ. The transcription factor
17		Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals.
18		Cell 1998;94(3):307-17. (In eng). DOI: 10.1016/s0092-8674(00)81474-9.
19	15.	Kwok A, Zvetkova I, Virtue S, et al. Truncation of Pik3r1 causes severe insulin resistance
20		uncoupled from obesity and dyslipidaemia by increased energy expenditure. Mol Metab
21		2020:101020. (In eng). DOI: 10.1016/j.molmet.2020.101020.

1	16.	Madhala-Levy D, Williams VC, Hughes SM, Reshef R, Halevy O. Cooperation between
2		Shh and IGF-I in promoting myogenic proliferation and differentiation via the MAPK/ERK
3		and PI3K/Akt pathways requires Smo activity. J Cell Physiol 2012;227(4):1455-64. (In
4		eng). DOI: 10.1002/jcp.22861.
5	17.	Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube
6		hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol
7		2001;3(11):1009-13. (In eng). DOI: 10.1038/ncb1101-1009.
8	18.	Gong Y, Yang J, Liu Q, et al. IGF1 Knockdown Hinders Myocardial Development through
9		Energy Metabolism Dysfunction Caused by ROS-Dependent FOXO Activation in the
10		Chicken Heart. Oxid Med Cell Longev 2019;2019:7838754. (In eng). DOI:
11		10.1155/2019/7838754.
12	19.	Sun XH, Wang X, Zhang Y, Hui J. Exosomes of bone-marrow stromal cells inhibit
13		cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p
14		targeting the PTEN/PI3K/AKT signaling pathway. Thromb Res 2019;177:23-32. (In eng).
15		DOI: 10.1016/j.thromres.2019.02.002.
16	20.	Pires KM, Torres NS, Buffolo M, et al. Suppression of Cardiac Autophagy by
17		Hyperinsulinemia in Insulin Receptor-Deficient Hearts Is Mediated by Insulin-Like
18		Growth Factor Receptor Signaling. Antioxid Redox Signal 2019;31(6):444-457. (In eng).
19		DOI: 10.1089/ars.2018.7640.
20	21.	Ren N, Wang M. microRNA-212-induced protection of the heart against myocardial
21		infarction occurs via the interplay between AQP9 and PI3K/Akt signaling pathway. Exp
22		Cell Res 2018;370(2):531-541. (In eng). DOI: 10.1016/j.yexcr.2018.07.018.

1	22.	Zhu HH, Wang XT, Sun YH, et al. MicroRNA-486-5p targeting PTEN Protects Against
2		Coronary Microembolization-Induced Cardiomyocyte Apoptosis in Rats by activating the
3		PI3K/AKT pathway. Eur J Pharmacol 2019;855:244-251. (In eng). DOI:
4		10.1016/j.ejphar.2019.03.045.
5	23.	McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the
6		risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
7		Blood 2014;124(25):3829-30. (In eng). DOI: 10.1182/blood-2014-10-604272.
8	24.	Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a
9		systematic review and meta-analysis. Blood 2016;128(1):138-40. (In eng). DOI:
10		10.1182/blood-2016-05-712828.
11	25.	Lang T, Yu L, Tu Q, et al. Molecular cloning, genomic organization, and mapping of
12		PRKAG2, a heart abundant gamma2 subunit of 5'-AMP-activated protein kinase, to
13		human chromosome 7q36. Genomics 2000;70(2):258-63. (In eng). DOI:
14		10.1006/geno.2000.6376.
15	26.	Hinson JT, Chopra A, Lowe A, et al. Integrative Analysis of PRKAG2 Cardiomyopathy iPS
16		and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and
17		Fibrosis. Cell Rep 2016;17(12):3292-3304. (In eng). DOI: 10.1016/j.celrep.2016.11.066.
18	27.	Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations
19		cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest
20		2002;109(3):357-62. (In eng). DOI: 10.1172/JCI14571.
21	28.	Matsui T, Nagoshi T, Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte
22		hypertrophy and survival. Cell Cycle 2003;2(3):220-3. (In eng).

1	29.	Gore-Panter SR, Hsu J, Hanna P, et al. Atrial Fibrillation associated chromosome 4q25
2		variants are not associated with PITX2c expression in human adult left atrial
3		appendages. PLoS One 2014;9(1):e86245. (In eng). DOI: 10.1371/journal.pone.0086245.
4	30.	Zhang Z, Wei S, Du H, et al. Zfhx3 is required for the differentiation of late born D1-type
5		medium spiny neurons. Exp Neurol 2019;322:113055. (In eng). DOI:
6		10.1016/j.expneurol.2019.113055.
7	31.	Tan KP, Kosuge K, Yang M, Ito S. NRF2 as a determinant of cellular resistance in retinoic
8		acid cytotoxicity. Free Radic Biol Med 2008;45(12):1663-73. (In eng). DOI:
9		10.1016/j.freeradbiomed.2008.09.010.
10	32.	Hu Q, Zhang B, Chen R, et al. ZFHX3 is indispensable for ER eta to inhibit cell proliferation
11		via MYC downregulation in prostate cancer cells. Oncogenesis 2019;8(4):28. (In eng).
12		DOI: 10.1038/s41389-019-0138-y.
13	33.	Kao YH, Hsu JC, Chen YC, et al. ZFHX3 knockdown increases arrhythmogenesis and
14		dysregulates calcium homeostasis in HL-1 atrial myocytes. Int J Cardiol 2016;210:85-92.
15		(In eng). DOI: 10.1016/j.ijcard.2016.02.091.
16	34.	Chen WK, Kuo WW, Hsieh DJ, et al. CREB Negatively Regulates IGF2R Gene Expression
17		and Downstream Pathways to Inhibit Hypoxia-Induced H9c2 Cardiomyoblast Cell Death.
18		Int J Mol Sci 2015;16(11):27921-30. (In eng). DOI: 10.3390/ijms161126067.
19	35.	Musi N, Yu H, Goodyear LJ. AMP-activated protein kinase regulation and action in
20		skeletal muscle during exercise. Biochem Soc Trans 2003;31(Pt 1):191-5. (In eng). DOI:
21		10.1042/bst0310191.

1	36.	Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by
2		activating AMP-activated protein kinase. Nature 2002;415(6869):339-43. (In eng). DOI:
3		10.1038/415339a.
4	37.	Sun MW, Lee JY, de Bakker PI, et al. Haplotype structures and large-scale association
5		testing of the 5' AMP-activated protein kinase genes PRKAA2, PRKAB1, and PRKAB2
6		[corrected] with type 2 diabetes. Diabetes 2006;55(3):849-55. (In eng). DOI:
7		10.2337/diabetes.55.03.06.db05-1418.
8	38.	Viollet B, Andreelli F, Jørgensen SB, et al. Physiological role of AMP-activated protein
9		kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 2003;31(Pt
10		1):216-9. (In eng). DOI: 10.1042/bst0310216.
11	39.	Zhang P, Hu X, Xu X, et al. AMP activated protein kinase-alpha2 deficiency exacerbates
12		pressure-overload-induced left ventricular hypertrophy and dysfunction in mice.
13		Hypertension 2008;52(5):918-24. (In eng). DOI:
14		10.1161/HYPERTENSIONAHA.108.114702.
15	40.	Cao H, Wang X, Ying S, Huang C. AMPK $\alpha 2$ deficiency enhanced susceptibility to
16		ventricular arrhythmias in mice by the role of β -adrenoceptor signaling. Exp Biol Med
17		(Maywood) 2018;243(8):708-714. (In eng). DOI: 10.1177/1535370218767389.
18	41.	Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation
19		risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort
20		and in vitro studies. Cardiovasc Diabetol 2014;13:123. (In eng). DOI: 10.1186/s12933-
21		014-0123-x.

1	42.	Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease.
2		Arterioscler Thromb Vasc Biol 2012;32(7):1552-62. (In eng). DOI:
3		10.1161/ATVBAHA.111.224915.
4	43.	Feng N, Anderson ME. CaMKII is a nodal signal for multiple programmed cell death
5		pathways in heart. J Mol Cell Cardiol 2017;103:102-109. (In eng). DOI:
6		10.1016/j.yjmcc.2016.12.007.
7	44.	Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and
8		Emerging Therapies. Circulation 2018;138(1):80-98. (In eng). DOI:
9		10.1161/CIRCULATIONAHA.118.030099.
10	45.	Nomani H, Bayat G, Sahebkar A, et al. Atrial fibrillation in β -thalassemia patients with a
11		focus on the role of iron-overload and oxidative stress: A review. J Cell Physiol
12		2019;234(8):12249-12266. (In eng). DOI: 10.1002/jcp.27968.
13	46.	Hoes MF, Grote Beverborg N, Kijlstra JD, et al. Iron deficiency impairs contractility of
14		human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail
15		2018;20(5):910-919. (In eng). DOI: 10.1002/ejhf.1154.
16	47.	Kanaan GN, Patten DA, Redpath CJ, Harper ME. Atrial Fibrillation Is Associated With
17		Impaired Atrial Mitochondrial Energetics and Supercomplex Formation in Adults With
18		Type 2 Diabetes. Can J Diabetes 2019;43(1):67-75.e1. (In eng). DOI:
19		10.1016/j.jcjd.2018.05.007.
20	48.	Wiersma M, Meijering RAM, Qi XY, et al. Endoplasmic Reticulum Stress Is Associated
21		With Autophagy and Cardiomyocyte Remodeling in Experimental and Human Atrial
22		Fibrillation. J Am Heart Assoc 2017;6(10) (In eng). DOI: 10.1161/JAHA.117.006458.

1	49.	Haushalter KJ, Schilling JM, Song Y, et al. Cardiac ischemia-reperfusion injury induces
2		ROS-dependent loss of PKA regulatory subunit RIa. Am J Physiol Heart Circ Physiol
3		2019;317(6):H1231-H1242. (In eng). DOI: 10.1152/ajpheart.00237.2019.
4	50.	Kamga Pride C, Mo L, Quesnelle K, et al. Nitrite activates protein kinase A in normoxia to
5		mediate mitochondrial fusion and tolerance to ischaemia/reperfusion. Cardiovasc Res
6		2014;101(1):57-68. (In eng). DOI: 10.1093/cvr/cvt224.
7	51.	Chung MK, Youn Wass SJ, Barnard J. Insights From Atrial Fibrillation Genomics: From
8		Bedside to Bench and Back Again. Cardiol Rev 2019;27(6):302-307. (In eng). DOI:
9		10.1097/CRD.00000000000267.
10	52.	Deshmukh A, Barnard J, Sun H, et al. Left atrial transcriptional changes associated with
11		atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol
12		2015;8(1):32-41. (In eng). DOI: 10.1161/CIRCEP.114.001632.
13		
14		
15		
16		
17		

1 Figure Legends

2 Figure 1. WGCNA correlation plot. WGCNA identified 64 distinct modules, which included a 3 'non correlated' module. 8 of the 48 modules had over-representation of AF genes in their 4 respective modules. Hierarchical clustering of the modules show clustering of AF 5 overrepresented modules 25, 39 and 42, and clustering of modules 11, 21, and 'not correlated'. 6 The size and shade of circle reflect strength of correlation, and color shows direction of 7 correlation. 8 9 Figure 2. PITX2 and coexpressed genes signaling pathways. Top canonical pathways include protein handling (e.g. 6- alanine degradation, valine, 4-aminobutyrate and glutamine degradation) 10

and and major signaling pathways (e.g. PI3K/AKT, G protein coupled receptor signaling, IGF-1,

12 PDGF signaling, renin-angiotensin and AMPK signaling pathways). PIK3 is critical in insulin

13 resistance and in the regulation of myogenic differentiation, myoblast proliferation, and myotube

14 hypertrophy.Activation of the PI3K-Akt signaling pathway, mediated through IGF-1, decreases

autophagy and apoptosis. AMPK activity and the resultant glycogen accumulation is correlated
with changes in metabolic pathways and Akt phosphorylation.

17

Figure 3. ZHFX3 and coexpressed genes signaling pathways. *RAS*, *PI3K* and *CREB* have
been linked to modulation of cardiomyocyte apoptosis.

20

Figure 4. Dual Risk Model for AF. Genes active during cardiac development may increase
genetic susceptibility to AF. Stressors, such as aging and obesity, may lead to increased cellular

- 1 stress, including metabolic, mitochondrial, oxidative, and unfolded protein stress. The
- 2 combination of genetic developmental susceptibility and accumulated stressors may lead to
- 3 overwhelmed or inadequate transcriptional responses which predisposes to AF occurrence.

Table 1. Candidate AF genes. Shaded headings indicate the 3 targeted groups of study genes. 1 Genes are listed in order of statistical significance of eOTL SNPs. 2

All Candidate Genes (n=233) Predicted by AF GWAS loci with significant cis-eQTL or prioritized by Nielsen ⁶ et al				
Any eQTL G				
Top GWAS SNP eQTLGenes (n=37) Ranked top 10	Other left atrial eQTL Genes (n=94) with cis-eOTL a <0.05	Remaining Nielsen prioritized genes without significant cis-eOTL(n=102)		
GNB4(1), MYOZ1(1), ARNT2(1),	SLC2A9, FAM13B, ADORA1,	SLC9B1, ARHGAP10, C10orf11, NAV2,		
AC016705.2 (1), CTXND1(1),	ENSG00000255864 (retired), GMCL1,	RBM20, HIP1R, C9orf3, AKAP6, AGBL4,		
SYNPO2L(1), HEATR2(1), TUBA8(1),	CMTM5, AP001062.7, IL25, EXT1,	NEURLI, UST, RPL3L, SLIT3, PHLDA1,		
RP11-1082L8.1 (1), CASQ2(1),	ABHD17C, MYOG, C5orf47, IL6R-	HSF2, MYO18B, FGF5, MIR6500,		
AC100858 (2), ENSG00000269728 -	AS1, IL6R, METTL11B, KDM1B,	GCOM1/MYZAP, FRMD4B, LHX3,		
retired (2), WIPF1(2), XXYLT1(2),	LINC00964, USP36, LRCH1, HAND2-	ZFHX3, GYPC, CASZ1, CDKN1A,		
ASAH1(2), SCN10A(2),	AS1, PTK2, TPMT, USP3-AS1,	PANDAR, PI16, GATA4, PLN, SLC35F1,		
LINC01426(2), ERBB4(2),	AC083843.3, SLC25A26, IGF1R,	SORL1, DGKB, CALU, OPN1SW, CDK6,		
LINC01629 (3), AC007620.2(3),	DNAH10OS, ZNF664, OR10P1,	CREB5, NR3C1, LOC102467213, EPHA3,		
SYNE2 (3), CAV1(3), DCST1-AS1(3),	PCM1, ENSG00000270028 (retired),	TEX41, CAMK2D, MYPN, SIRT1,		
RN7SL356P(4), KCND3(4), THRB(4),	RAB7L1, ERBB2, GYG1, GSDMB,	MYOCD, REEP1, CFL2, ATXN1, HCN4.		
SSPN(4), CEP68(5), MTSS1(6),	STAG3L2, PRRX1, CCDC92, PROZ,	KIF3C, CAND2, KCNH2, LINC00540,		
<i>PKP2</i> (6), <i>AC113382.1</i> (7), <i>SCN5A</i> (7),	SPATS2L, COG5, DEK, PCCB,	LINC00621, SGCG, SMAD7, HAND2,		
GJA5(7), KCNJ5 (8), C21orf2(10),	MEX3C, PHLDB2, SLC27A6,	KCNN3, PITX2, NACA, LINC00477,		
AC113382.2 (10), TBX5(10)	MRPL35P2, C11orf45, WNT3, MSL1,	NKX2-5, LINC01142, LRRC10, AGAP5,		
	FBXO32, CAV2, NSG2, MTHFD1,	NUDT13, IRF2BPL, LINC01426, ESR2,		
	AC098798.1, SCMH1, HSPG2, NSF,	MIR548AZ, MYOT, NPY6R, WNT8A,		
	GET4, P2RX2, CUL4A, FKBP7,	PPFIA4, ANXA4, MYH6, MYH7, CYTH1,		
	DMTN, F10, PFDN1, DPF3,	LRIGI, HERCI, NUCKSI, SLC4IAI,		
	SNRNP27, RNF144B, SAT2, PM20D1,	ORMDL3, ZPBP2, GTF2I, GTF2IRD2,		
	C2orf/4, USP34, FBXL22, KCNN2,	LOC101926943, PPP2R3A, PLCXD2,		
	MYRFL, YWHAE, ARLI7A, SMIM8,	NRBF2, REEP3, FBRSL1, MIR548N,		
	CIPSI, THAP9-ASI, PNMT, AHSA2,	IIN, IIN-ASI, XPO/, FXR2, SOX15,		
	PGAP3, GSDMA, AC02/11/.1,	INFSF12, INFSF12-TNFSF13, CRK,		
	KIAA1841, ZBIB25, MED24,	MYOIC, CGA		
	LKKUS/A2, KABSIP, HLA-B, MICA,			
	PSORSICI, HLA-C			

AF = atrial fibrillation; *cis*-eQTL = cis expression quantitative trait loci; GWAS = genome wide

association study. (in parentheses): rank of GWAS SNP among the top 10 eQTL SNPs.

4 5 6

1 Table 2. Genes identified by significant left atrial cis-eQTLs but not prioritized by Nielsen,

2 et al^6 .

HEATR2,GET4, LINC01314, RP11-210M15.2, RP11-1082L8.1, *MTSS1*, LINC00964, RP11-145M9.4, AC007620.3, RP11-7F17.1, RP11-7F17.7, RN7SL356P, PCM1, AP000330.8, I. RP11-806011.1, RP11-307C12.11, AC113382.1, AC083843.1, AC098798.1, *ZBTB25*, RP11-325L7.2, AP001062.7, RP11-444D3.1, *NSG2*, *IL6R-AS1*, C11orf45, C21orf2, *SLC2A9*, *ADORA1*, *MYOG*, *SNRNP27*, *CMTM5*, *IL25*, *EXT1*, *ABHD17C*, C5orf47, IL6R, *METTL11B*, *TPMT*, *RNF144B*, *LRCH1*, *USP3-AS1*, *FBXL22*, *DNAH10OS*, *ZNF664*, *CCDC92*, *OR10P1*, *RAB7L1*, *PM20D1*, *ERBB2*, *MSL1*, *PNMT*, *PGAP3*, *GSDMA*, *MED24*, *GYG1*, *STAG3L2*, *PRRX1*, *PROZ*, *F10*, *COG5*, *PCCB*, *MRPL35P2*, *NSF*, *ARL17A*, *LRRC37A2*, *CTPS1*, *P2RX2*, *DMTN*, *PFDN1*, *SAT2*, C2orf74, *AHSA2*, *KIAA1841*, *MYRFL*, *RAB3IP*, *SMIM8*, *THAP9-AS1*, *HLA-B*, *MICA*, *PSORS1C1*, *HLA-C*, ENSG00000270028 (retired)

3

4

1 Table 3.

Modules with AF gene overrepresentation (p<0.05)*	Total number of genes in module	# AF genes in module	Hub genes of module	Pathways identified by IPA and GSEA
M21	236	9 (PRRX1HSPG2 SLIT3 EXT1 TBX5 HIP1R METTL11B PHLDA1 NAV2)	ABTB2; SLC8A3	Intracellular ion homeostasis Apelin Cardiomyocyte Signaling Pathway
M2	1082	23 (DMTN FAM13B KIAA1841 CEP68 THAP9-AS1 FRMD4B MYH6 KCND3 XP07 FBX032 SGCG ATXN1 PPP2R3A CDK6 SORL1 MY0CD KCNN3 CUL4A IGF1R ZFHX3 NR3C1 TTN)	ARHGEF12; PIKFYVE; KIF1B; TEAD1; ICE1; PBRM1; UBR2; NCOA2; ARFGEF2; DENND5B	Heme metabolism Protein Kinase A Signaling
Not Correlated	1468	18 (LINC01629 AC007686.1 TNFSF12-TNFSF13 COG5 GTF2IRD2 C2orf74 ARL17A ARNT2 MICA NACA RAB3IP AC016705.2 CCDC92 LINC01426 LINC01426 DGKB DNAH10OS KIF3C)		
M25	230	7 (C9orf3 MY01C MY018B RBM20 CAV1 CFL2 MYPN)	DNAJB5; SLMAP	Myogenesis Remodeling of Epithelial Adherens Junctions Gap Junction Signaling
M11	361	9 (SYNE2 IL6R LRRC10 MTSS1 PTK2 ERBB2 ESR2 ADORA1	RCOR2; ADAMTS7; CXXC4; TESK2	Ephrin A Signaling

		HCN4)		
M42	148	5	PPP1R3B	
		(DNAAF5		ILK Signaling
		USP3-AS1		Integrin Signaling
		FBXL22		Actin Nucleation by ARP-WASP
		NEURL1		Complex
		AC083843.2)		-
M39	156	5 (CMTM5	AC083902.2; ABRA	TNFA signaling via NFKB
		HLA-C		Endoplasmic Reticulum Stress Pathway
		SMIM8		Protein Kinase A Signaling
		CASZ1		
		CREB5)		
M24	232	6 (CTXND1	LRRC59; SEC13	Protein Secretion
		ORMDL3		Unfolded protein response
		OPN1SW		Gap Junction Signaling
		PM20D1		Remodeling of Epithelial Adherens
		ANXA4		Junctions
		CALU)		

*listed in descending order of statistical significance









- 2 Figure 3. *ZHFX3* and coexpressed genes signaling pathways

Dual Risk Model

In Genetically Susceptible Patients, Inadequate Transcriptional Responses to Stress Predispose to AF in Later Life



Figure 4. Dual Risk Model for AF.

1 SUPPLEMENTAL MATERIALS

Supplemental Figure 1. Supplemental Figure 2.	All Candidate genes by function and location Most commonly coexpressed non-GWAS genes		
Supplemental Figure 3.	Top significant IPA® canonical pathways for the coexpression networks of each candidate AF gene group		
Supplemental Table 1.	Top pathways and upstream regulators within each AF candidate gene group		
Supplemental Excel 1.	Coexpression partners of 225 candidate AF genes.		
Supplemental Excel 2.	WGCNA modules- LA genes and hub genes		
Supplemental Excel 3.	All significant top canonical pathways for the coexpression networks of the All Candidate Genes (n=233 genes)		
Supplemental Excel 4.	All significant top canonical pathways for the coexpression networks of the Any eQTL Genes (n=131 genes).		
Supplemental Excel 5.	All significant top canonical pathways for the coexpression networks of the Top GWAS SNP eQTL Genes (n=37 genes).		
Supplemental Excel 6.	IPA analysis results of WGCNA modules		
Supplemental Excel 7.	GSEA of WGCNA Modules		
Supplemental Excel 8.	eQTL GWAS SNPs		
Supplemental Excel 9.	Top 5 significant canonical pathways for each candidate AF gene and coexpression partners.		
Supplemental Pdfs	IPA analysis results of candidate AF gene and coexpression partners		





6 Gene Function. Of the 233 candidate atrial fibrillation genes 12% encode transcription

7 regulators, 12% enzymes, 5% transporters, 4% ion channels, 4% kinases and 3% peptidases. **B.**

8 Categories of Gene Location. Of the 233 candidate atrial fibrillation genes 32% are in the

9 plasma membrane, 22% in the nucleus, 17% in the cytoplasm and 7% in the extracellular space.

10

5

11



2 Supplemental Figure 2. Most commonly coexpressed non-GWAS genes. PRKAA2 and

4 candidate genes, followed by *PTGFRN*, *TLN1*, *SLMAP*, *PDLIM5* and *MSRB3*.

5

³ CAMK2B are non AF GWAS genes that are most frequently coexpressed with AF GWAS



B.



1 C.



1	
т	

D.

	All Candidate Genes	All eQTL Genes	Top GWAS SNP eQTLGenes	
Cancer Signaling	2	2	3	
Calcium/GPCR signaling	2	3	4	
Developmental signaling	6	7	4	
Energy/Metabolism signaling	10	8	7	
Inflammation	1	1	7	
Nerve signaling	2	2	2	
Structural signaling	6	6	4	
Stress/Injury signaling	8	10	5	
Other	3	1	4	

2

Supplemental Figure 3. Top significant IPA® canonical pathways for the coexpression 3 4 networks of each candidate AF gene list. IPA canonical pathways for each candidate gene 5 were ranked from lowest to highest p-value and the top 5 significant canonical pathways listed 6 for each gene (See Supplemental Excel file 8, Supplemental Figure 3-5). Displayed here is the 7 percentage of genes for which canonical pathways were listed in the top 5. Data are displayed by 8 gene lists. A. All Candidate Genes (N=225; data not available for 8 genes, see text). 9 Mitochondrial dysfunction, oxidative phosphorylation, epithelial adherens junction signaling, 10 sirtuin signaling pathway and actin cytoskeleton pathway were the most frequent pathways listed among the top 5 canonical pathways. **B. Any eQTL Genes** (n=131). Epithelial adherens junction 11 signaling, mitochondrial dysfunction and oxidative phosphorylation, germ cell-Sertoli cell 12 junction singnaling and axonal guidance signaling were the most frequent pathways listed among 13 the top 5 canonical pathways. C. Top GWAS SNP eQTL Genes (n=37). EIF2 signaling, axonal 14 guidance signaling, regulation of eIF4 and p70S6K signaling, oxidative phosphorylation, and 15 mitochondrial dysfunction were the most frequent pathways listed among the top 5 canonical 16 pathways. D. Frequency of significance of each pathway for the 3 gene lists. 17 18 Energy/Metabolism signaling followed by Stress/Injury signaling, followed by Developmental signaling and Structural signaling were the most frequent themes in the All Candidate Genes list. 19

- 1 Stress/Injury signaling, followed by Energy/Metabolism signaling, Developmental signaling, and
- 2 Structural signaling were the most frequent themes in the All eQTL Genes list.
- 3 Energy/Metabolism signaling and Inflammation most commonly appeared in the Top GWAS
- 4 SNP eQTL Genes list.
- 5

1 Supplemental Table 1. Top pathways and upstream regulators within each AF candidate

2 gene list

	Top GWAS SNP eQTL Genes (n=37)	All eQTL Genes (n=131)	All Candidate Genes (n=233)
Top Canonical Pathways	 G Beta Gamma Signaling Ceramide Degradation Gi Signaling Sphingosine and Sphingosine -1- phosphate Metabolism Axonal Guidance Signaling 	 IL-15 Production G Beta Gamma Signaling Caveolar-mediated Endocytosis Signaling Phagosome Maturation Agrin Interactions at Neuromuscular Junction 	 Cardiac Hypertrophy Signaling (Enhanced) Axonal Guidance Signaling Cardiomyocyte Differentiation via BMP Receptors Ephrin Receptor Signaling Factors Promoting Cardiogenesis in Vertebrates
Top upstream regulators	• miR-4455 • <i>MEF2C</i> • <i>PTCH1</i> • <i>HEY2</i>	 <i>ESRRA</i> miR-450a-1-3p <i>LRIG3</i> Phenylacetate 	• MYOCD • ESRRA • NKX2-5 • HEY2 • MEF2C
Top Networks	 Cancer, Organismal Injury and Abnormalities, Respiratory Disease Organ Morphology, Organismal Injury and Abnormalities, Skeletal and Muscular Disorders 	 Developmental Disorder, Hereditary Disorder, Organismal Injury and Abnormalities Cardiac Arrhythmia, Cardiovascular Disease, Organismal Injury and Abnormalities Auditory Disease, Cardiovascular Disease, Dental Disease Organismal Injury and Abnormalities, Skeletal and Muscular Disorders, Infectious Diseases Cancer, Organismal Injury and Abnormalities, Respiratory Disease 	 Cardiovascular Disease, Organismal Injury and Abnormalities, Skeletal and Muscular Disorders Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Cancer Cardiovascular Disease, Hereditary Disorder, Organismal Injury and Abnormalities Inflammatory Disease, Infectious Diseases, Lipid Metabolism Cell Cycle, Developmental Disorder, Hereditary Disorder

3